Company intelligence / Profile preview

AlzeCure Foundation

Ownership: Private
Development stage: Other

Overview

AlzeCure has advanced its lead program NeuroRestore ACD856 into clinical development, with preparatory work underway for Phase II studies. Preclinical data show neuroprotective and potential disease-modifying effects. The second Alzheimer’s project, Alzstatin, is preparing its latest molecule ACD680 for clinical trials. In pain management, the TrkA-NAM program has selected a candidate drug with promising preclinical efficacy comparable to Tanezumab.

Therapeutic areas: RheumatologyOphthalmologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AlzeCure Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlzeCure Foundation.

Explore the full profile